Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin.

Chakraborty S, Utter MB, Frias MA, Foster DA. Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin. Cancer Lett. 2021 12 01; 522:164-170.

View in: PubMed

subject areas

Apoptosis
Cell Cycle
Cell Line, Tumor
Cyclin-Dependent Kinase Inhibitor p16
Drug Resistance, Neoplasm
E2F Transcription Factors
Humans
Lung Neoplasms
Male
Mutation
Phosphorylation
Prostatic Neoplasms
Retinoblastoma Protein
Signal Transduction
Sirolimus
Transforming Growth Factor beta

authors with profiles

David A. Foster

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support